In March 6th, Lilly pharmaceuticals announced in Shanghai that its CDK4/6 inhibitor, China’s first breast cancer indication, was officially listed in China. It is also the first and only CDK4/6 inhibitor approved for early breast cancer in China.
CDK4 / 6 inhibitors are popular target drugs in the field of tumor therapy. In China, Pfizer’s piperacillin was approved in August 2018, becoming the first CDK4 / 6 inhibitor listed in China. In March 2021, Lilai and the upper breast cancer indication of breast cancer was listed in China, and the second CDK4/6 inhibitor approved in China.
“With the advent of early breast cancer indications, Lilly China has also entered a new and better stage in the development of cancer.” Ji Liwen, President and general manager of Lilly China, told surging news reporters that the tumor business is an important business department of Lilly China, and the only choice is a heavy drug for Lilly global, with a revenue contribution of more than US $1 billion in 2021.
In fact, in addition to Pfizer and Eli Lilly, many pharmaceutical companies in China have laid out CDK4 / 6 inhibitors.
On February 26 this year, Jiangsu Hengrui Medicine Co.Ltd(600276) held the listing meeting of CDK4 / 6 inhibitor darcili, which is the first Chinese original CDK4 / 6 inhibitor independently developed in China. Earlier, on January 7, Xiansheng pharmaceutical also announced that the application for the listing of the first indication (small cell lung cancer) new drug for injection of tralacili, a CDK4 / 6 inhibitor developed by the company in cooperation with G1 therapeutics in the United States, had been included in the priority review by the State Drug Administration.
In addition to the original research into the Bureau, the following generic drugs also make the competition in the field of CDK4 / 6 inhibitors more intense. Take Pfizer’s piperacillin as an example, its Chinese compound patent will expire on January 10, 2023. Although there is still nearly a year to go, relevant enterprises have made early layout, among which Qilu pharmaceutical’s four generic drugs piperacili capsule has been approved for listing in December 2020.
For the competitive situation in the field of CDK4 / 6 inhibitors, Ji Liwen told surging news reporters that Lilly welcomes such benign competition and hopes to see a two-way flow between China’s innovative drugs and global innovative drugs, that is, not only global innovative drugs enter China, but also more Chinese new drugs will go global in the future to benefit patients.
It is worth mentioning that, at the end of 2021, the negotiations on the indication of advanced breast cancer were successfully entered into the national health insurance directory. This is the first time that the national health insurance directory has been incorporated into the CDK4/6 inhibitor. It is also the only CDK4/6 inhibitor that has been successfully included in the national health insurance directory through medical insurance negotiations.
According to Ji Liwen, the final decline in the national health care negotiations at the end of last year reached 60%. In the whole process of drug negotiation, Lilly will not only actively cooperate with the government, but also flexibly communicate with the headquarters according to the situation of China, so as to achieve flexible price negotiation.
Gao Tong, vice president of Lilly China government and company affairs, revealed that with the official listing of early breast cancer indications, Lilly hopes to enter this certificate in some city this year before the national health insurance directory.
